Cargando…

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases

Vedolizumab, a monoclonal antibody directed against integrin α4β7, is an effective treatment for inflammatory bowel diseases. However, a significant number of patients do not achieve steroid-free clinical remission in the first year of treatment. An early identification of these patients is one of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertani, Lorenzo, Caviglia, Gian Paolo, Antonioli, Luca, Pellicano, Rinaldo, Fagoonee, Sharmila, Astegiano, Marco, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Blandizzi, Corrado, Costa, Francesco, Ribaldone, Davide Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290461/ https://www.ncbi.nlm.nih.gov/pubmed/32370274 http://dx.doi.org/10.3390/jcm9051323

Ejemplares similares

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?
por: Bonagura, Gabriele Antonio, et al.
Publicado: (2016)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Inflammatory Bowel Disease Nurse—Practical Messages
por: Rosso, Chiara, et al.
Publicado: (2021)

A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
por: Bretto, Elisabetta, et al.
Publicado: (2023)

History of Inflammatory Bowel Diseases
por: Actis, Giovanni Clemente, et al.
Publicado: (2019)

2013 Update on Celiac Disease and Eosinophilic Esophagitis
por: Pellicano, Rinaldo, et al.
Publicado: (2013)

Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014
por: Saracco, Giorgio Maria, et al.
Publicado: (2016)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Does the Microbiota Play a Pivotal Role in the Pathogenesis of Irritable Bowel Syndrome?
por: Fagoonee, Sharmila, et al.
Publicado: (2019)

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Response to: Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2016)

Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Finally, it is Bismuth's Time
por: Ribaldone, Davide G., et al.
Publicado: (2017)

Strategies for Helicobacter pylori eradication in the year 2020
por: Pellicano, Rinaldo, et al.
Publicado: (2020)

Helicobacter pylori and Respiratory Diseases: 2021 Update
por: Durazzo, Marilena, et al.
Publicado: (2021)

Comment on “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis
por: Rosso, Chiara, et al.
Publicado: (2022)

Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Inflammatory Bowel Diseases: It's Time for the Adenosine System
por: Antonioli, Luca, et al.
Publicado: (2020)

The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review
por: Armandi, Angelo, et al.
Publicado: (2021)

The Evolving Incidence of Hepatitis C Virus Infection in Italy
por: Pellicano, Rinaldo, et al.
Publicado: (2012)

Response to: Reply on “Renewed Helicobacter pylori Management and Therapy in 2015”
por: Fagoonee, Sharmila, et al.
Publicado: (2016)

One or Two Weeks of Treatment with Helicobacter pylori “Standard” Triple Therapy in the Year 2015?
por: Pellicano, Rinaldo, et al.
Publicado: (2015)

Promises of Fibroblast Growth Factor Receptor–Directed Therapy in Tailored Cancer Treatment
por: Fagoonee, Sharmila, et al.
Publicado: (2020)

Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification
por: Olivero, Antonella, et al.
Publicado: (2022)

Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2hiqrn8hlj3ntfijobvtsd13ao